Pancreatic Cancer - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Pancreatic Cancer Emerging Therapy and TPP Insights

Thelansis's "Pancreatic Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Pancreatic Cancer Overview

Pancreatic cancer is a heterogeneous group of malignancies arising in the pancreas, with pancreatic ductal adenocarcinoma (PDAC) representing the predominant form. Early-stage disease may produce few or nonspecific symptoms, resulting in frequent diagnosis at locally advanced or metastatic stages. Clinical manifestations can include jaundice, abdominal or back pain, unexplained weight loss, anorexia, digestive disturbances, and new-onset diabetes, although presentation varies with tumor location and disease extent. Treatment is guided by stage, resectability, tumor biology, and patient fitness and may involve surgery, chemotherapy, radiation, targeted therapy, or multimodal combinations. Molecular profiling can identify patients with actionable alterations involving homologous-recombination repair, mismatch repair, gene fusions, HER2, and selected KRAS variants. The treatment landscape is evolving, with KRAS-directed therapy now entering clinical practice for previously treated metastatic PDAC. Despite advances, tumor heterogeneity, stromal barriers, metastatic spread, and acquired resistance continue to limit durable disease control.

Key Highlights

• In the United States, pancreatic cancer incidence cases are projected to increase from 66,470 in 2026 to 73,061 by 2036.
• Pancreatic cancer is an aggressive malignancy often diagnosed at an advanced stage.
• High recurrence rates and limited treatment options remain major clinical challenges.
• Significant unmet need remains for early detection and therapies that improve survival.

Market Overview

• The Germany pancreatic cancer market is projected to grow from $255M in 2026 to $745M by 2036.
• Market growth is driven by:
• Increasing adoption of targeted therapies and novel treatment combinations
• Advances in precision oncology and immunotherapy research

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Amgen
• Akeso
• Verastem, Inc.
• ImmunityBio, Inc.
• Can-Fite BioPharma
• Anova Innovation Limited
• Qilu Pharmaceutical Co., Ltd.
• Astellas Pharma Global Development, Inc.
• Innovent Biologics (Suzhou) Co. Ltd.
• BPGbio
• Lokon Pharma AB
• XBiotech, Inc.
• CivaTech Oncology
• Bold Therapeutics, Inc.
• Diakonos Oncology Corporation
• CARsgen Therapeutics Co., Ltd.
• Amplia Therapeutics Limited
• Revolution Medicines, Inc.
• Bristol-Myers Squibb
• Cue Biopharma
• Suzhou Transcenta Therapeutics Co., Ltd.
• Incyte Corporation
• Boehringer Ingelheim
• NGM Biopharmaceuticals, Inc.
• Pfizer